Table 1.

Trastuzumab (6 preparation of a Herceptin® antibody lot, HER5) glycoforms identified by PA-IPC method.

PA-IPC
Glycoform		RT, min	Average RA, %	RSD% (RT), n = 6	RSD% (RA), n = 6
G0-2GlcNAc		11.45	0.02	0.12	36.51
G0 F-2GlcNAca		13.60	0.02	0.09	0.00
G0-GlcNAca		14.87	0.55	0.08	4.74
G0 F-GlcNAc		17.09	0.99	0.08	2.98
G0a		18.19	3.84	0.07	1.52
G1-GlcNAc		19.59	0.09	0.06	8.52
G0 Fa		20.17	39.19	0.07	0.23
G0+ GlcNAc		21.04	0.07	0.08	11.02
G1 Fa – GlcNAc		21.32	0.19	0.05	5.34
M5a		21.84	1.83	0.06	1.33
G1 Fb – GlcNAc		22.43	0.67	0.07	1.21
G1a		22.62	1.66	0.07	0.91
G1ʹa		23.34	0.61	0.07	1.38
G0 F+ GlcNAca		24.05	0.12	0.06	4.76
G1 Faa		24.47	29.09	0.06	0.62
G1 Fba		25.24	9.62	0.06	0.60
G1-GlcNAc+SA		25.70	0.12	0.11	6.36
G1+ GlcNAc		26.02	0.04	0.24	9.80
M6		26.46	0.04	0.24	10.65
M5 F		26.78	0.08	0.13	9.22
G1+ SA		26.96	0.18	0.05	3.13
G1 F-GlcNAc+SA & G2a		27.59	0.55	0.06	1.79
G1 F+ GlcNAc		28.21	0.22	0.05	2.55
G1 Fa + SAa		28.69	0.44	0.06	2.67
G2 Fa		29.32	6.79	0.06	0.77
G1 Fb + SA		29.80	0.34	0.06	3.72
G1+ SA+M1		30.37	0.09	0.04	19.88
G2+ SA		31.34	0.14	0.05	4.52
M7		31.75	0.08	0.14	7.30
G2 Fa+GlcNAc		32.04	0.06	0.04	15.21
G2 Fb+GlcNAc		32.61	0.05	0.04	9.68
G2 Fa + SAa		33.03	0.64	0.05	1.17
G2 Fb + SA		33.44	0.24	0.05	0.00
G1+ SA+M2		33.79	0.10	0.06	10.00
G1F+SA+M2		34.51	0.05	0.05	12.65
G2+ SA+M1		35.37	0.08	0.05	0.00
M8		35.65	0.11	0.04	4.56
G2 + 2SA		36.02	0.04	0.03	0.00
G2 F + 2SAa		37.02	0.38	0.05	1.35
G2 + 2SA+M1		39.17	0.06	0.04	0.00
Unknown		0.53

^aGlycoforms identified when 2-AB glycan derivatization is used.

Glycoforms are presented in the order they appear on the chromatogram.

RT: retention time, RA: relative area, RSD: relative standard deviation.